313 Results for "

mAbs

" in MedChemExpress (MCE) Product Catalog:
Products (313)

313 Results for "mAbs" in MCE Product Catalog:

11
11 Publications Verification
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
loading...
    loading...
11
11 Publications Verification
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P9926
CAS No.: 1190264-60-8
Synonyms: REGN-668; SAR-231893

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P99340
CAS No.: 2423014-07-5
Synonyms: VIR 7831; GSK-4182136

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P99032
CAS No.: 1228763-95-8
Synonyms: IPH2201
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15971A
CAS No.: 185991-24-6
Synonyms: GENZ-644494
Target:  

CXCR HIV

Research Areas:  

Infection Endocrinology

AMD 3465 (GENZ-644494) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12 AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15971
CAS No.: 185991-07-5
Synonyms: GENZ-644494 hexahydrobromide
Target:  

CXCR HIV

Research Areas:  

Infection Endocrinology

AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12 AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99006
CAS No.: 931402-35-6
Synonyms: MORab-009

Target:  

Mesothelin

Research Areas:  

Cancer

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99434
CAS No.: 2378692-15-8
Synonyms: KY1005; SAR445229

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P991451
Synonyms: SGN-ALPV Antibody; h12F3

Target:  

Phosphatase

Research Areas:  

Cancer

Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9801
Synonyms: SARS-CoV-2 (2019-nCoV) Spike RBD Antibody

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99113
CAS No.: 1299440-37-1
Synonyms: MEDI-551
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99435
CAS No.: 2509447-07-6
Synonyms: BRII-196

Target:  

SARS-CoV

Research Areas:  

Infection

Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12843
CAS No.: 189232-42-6
Purity:  98.93%
Target:  

CDK ERK

Research Areas:  

Cancer

Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99221
CAS No.: 880266-57-9
Synonyms: RN-624; PF 4383119
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99253
CAS No.: 1159266-37-1
Synonyms: KW-0761

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990110
Synonyms: Mab158

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Lecanemab (Mouse IgG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IgG2a sequence. Lecanemab (Mouse IgG2a) almost abolishes accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IgG2a) holds promise for research in the field of Alzheimer's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99025
CAS No.: 953400-68-5
Synonyms: TNX-650; MILR1444A; RG3637

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
loading...
    loading...